First humans receive experimental arthritis drug in groundbreaking safety trial
NCT ID NCT07234773
Summary
This is the first time researchers are testing a new drug called KT501 in people with rheumatoid arthritis. The main goal is to check if it's safe and see how the body processes it. About 24 adults with active RA will receive one injection and be monitored for 12 weeks, with some followed longer to track their immune cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kali Study Site
RECRUITINGBayswater, Australia
Conditions
Explore the condition pages connected to this study.